Cross-sectional study on exhaled nitric oxide in relation to upper airway inflammatory disorders with regard to asthma and perennial sensitization.
FeNO
asthma
exhaled nitric oxide
nasal polyposis
population-based
rhinitis
Journal
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
ISSN: 1365-2222
Titre abrégé: Clin Exp Allergy
Pays: England
ID NLM: 8906443
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
30
11
2020
accepted:
15
09
2021
pubmed:
19
9
2021
medline:
1
4
2022
entrez:
18
9
2021
Statut:
ppublish
Résumé
Fractional exhaled nitric oxide (FeNO) is a well-known marker of type-2 inflammation. FeNO is elevated in asthma and allergic rhinitis, with IgE sensitization as a major determinant. We aimed to see whether there was an independent association between upper airway inflammatory disorders (UAID) and FeNO, after adjustment for asthma and sensitization, in a multi-centre population-based study. A total of 741 subjects with current asthma and 4155 non-asthmatic subjects participating in the second follow-up of the European Community Respiratory Health Survey (ECRHS III) underwent FeNO measurements. Sensitization status was based on measurement of IgE against airborne allergens; information on asthma, UAID and medication was collected through interview-led questionnaires. Independent associations between UAID and FeNO were assessed in adjusted multivariate regression models and test for interaction with perennial sensitization and asthma on the relation between UAID and FeNO were made. UAID were associated with higher FeNO after adjusting for perennial sensitization, asthma and other confounders: with 4.4 (0.9-7.9) % higher FeNO in relation to current rhinitis and 4.8 (0.7-9.2) % higher FeNO in relation to rhinoconjunctivitis. A significant interaction with perennial sensitization was found in the relationship between current rhinitis and FeNO (p = .03) and between rhinoconjunctivitis and FeNO (p = .03). After stratification by asthma and perennial sensitization, the association between current rhinitis and FeNO remained in non-asthmatic subjects with perennial sensitization, with 12.1 (0.2-25.5) % higher FeNO in subjects with current rhinitis than in those without. Current rhinitis and rhinoconjunctivitis was associated with higher FeNO, with an interaction with perennial sensitization. This further highlights the concept of united airway disease, with correlations between symptoms and inflammation in the upper and lower airways and that sensitization needs to be accounted for in the relation between FeNO and rhinitis.
Sections du résumé
BACKGROUND
Fractional exhaled nitric oxide (FeNO) is a well-known marker of type-2 inflammation. FeNO is elevated in asthma and allergic rhinitis, with IgE sensitization as a major determinant.
OBJECTIVE
We aimed to see whether there was an independent association between upper airway inflammatory disorders (UAID) and FeNO, after adjustment for asthma and sensitization, in a multi-centre population-based study.
METHODS
A total of 741 subjects with current asthma and 4155 non-asthmatic subjects participating in the second follow-up of the European Community Respiratory Health Survey (ECRHS III) underwent FeNO measurements. Sensitization status was based on measurement of IgE against airborne allergens; information on asthma, UAID and medication was collected through interview-led questionnaires. Independent associations between UAID and FeNO were assessed in adjusted multivariate regression models and test for interaction with perennial sensitization and asthma on the relation between UAID and FeNO were made.
RESULTS
UAID were associated with higher FeNO after adjusting for perennial sensitization, asthma and other confounders: with 4.4 (0.9-7.9) % higher FeNO in relation to current rhinitis and 4.8 (0.7-9.2) % higher FeNO in relation to rhinoconjunctivitis. A significant interaction with perennial sensitization was found in the relationship between current rhinitis and FeNO (p = .03) and between rhinoconjunctivitis and FeNO (p = .03). After stratification by asthma and perennial sensitization, the association between current rhinitis and FeNO remained in non-asthmatic subjects with perennial sensitization, with 12.1 (0.2-25.5) % higher FeNO in subjects with current rhinitis than in those without.
CONCLUSIONS & CLINICAL RELEVANCE
Current rhinitis and rhinoconjunctivitis was associated with higher FeNO, with an interaction with perennial sensitization. This further highlights the concept of united airway disease, with correlations between symptoms and inflammation in the upper and lower airways and that sensitization needs to be accounted for in the relation between FeNO and rhinitis.
Substances chimiques
Allergens
0
Nitric Oxide
31C4KY9ESH
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
297-311Subventions
Organisme : Sociedad Espanola de Neumologia y Cirygia Torácia (SEPAR 1001/2010)
Organisme : Centro de Exalencia Severo Ochoa 2019-2023 (CEX2018-000806-S)
Organisme : Servicio Andaluz de Salud
Organisme : Swedish Research Council for Health, Working Life and Social Research
Organisme : Västerbotten County Council ALF grant
Organisme : CERCA program
Organisme : ResMed Foundation, California, USA
Organisme : Orkuveita Reykjavíkur (Geothermal plant)
Organisme : University of Icelnd Research Fund
Organisme : German Research Foundation MA 711/6-1
Organisme : German Reasearch Foundation NO 262/7-1
Organisme : Agence Nationale de la Santé, Région Ile de France, domaine d'intérêt majeur
Organisme : German Research Foundation HE 3294/01-1
Organisme : Westerm Norway Regional Health Authorities grant no 911631
Organisme : Norwegian Research Council grant no 214123
Organisme : Cariverona foundation
Organisme : Vegagerdin (The Icelandic Road Administration)
Organisme : Talecris Biotherapeutics GmbH
Organisme : Abott Diagnostics
Organisme : Freiwillige Akademische Gesellschaft
Organisme : The Lung Leagues of the cantons Basel Stadt/Basel, Landschaft, Geneva, Ticino, Valais, and Zurich
Organisme : SUVA
Organisme : Ministère de la Santé, Programme Hospitalier de Recherche Clinique 187 (PHRC) national 2010
Organisme : European Commission 018996 (GABRIEL)
Organisme : Wellcome Trust WT 084703MA
Organisme : the canton governments of Aargan, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, Valais and Zurich
Organisme : Swiss Lung League
Organisme : Federal Office for Public Health
Organisme : Federal Office of Roads and Transport
Organisme : Swiss National Science Foundation (grants no 4026-028099)
Organisme : Federal Office for Forest, Environment and Landscape
Organisme : Comité Scientifique AGIRadom 2011
Organisme : Estonian Ministry of Education (grant code SF0180060s09)
Organisme : Estonian Research Council Personal Research Grant no 562
Organisme : National Health & Medical Research Council Australia
Organisme : Research Foundation Flanders (grant code G.0.0410.08.N.10)
Organisme : Medical Research Council (Grant Number 92091)
Organisme : National Health & Medical Research Council
Organisme : Research Foundation Flanders (FWO)
Organisme : Estonia
ID : Tartu
Organisme : Estonia
ID : SF0180060s09
Organisme : Estonian Ministry of Education
Organisme : CSP VA
ID : 562
Pays : United States
Organisme : Ministère de la Santé, Programme Hospitalier de Recherche Clinique (PHRC)
Organisme : INSERM U897 Université Bordeaux Segalen
Organisme : German Research Foundation
ID : 3294/10-1
Organisme : Hamburg-German Research Foundation
ID : 711/6-1
Organisme : Hamburg-German Research Foundation
ID : 262/7-1
Organisme : The Landspítali University Hospital Research Fund
Organisme : University of Iceland Research Fund
Organisme : ResMed Foundation
Organisme : Italian Ministry of Health
Organisme : Chiesi Farmaceutici SpA
Organisme : Cariverona Foundation
Organisme : Education Ministry (MIUR)
Organisme : Norwegian Research Council
ID : 214123
Organisme : Western Norway Regional Health Authorities
ID : 911631
Organisme : Bergen Medical Research Foundation
Organisme : Fondo de Investigación Sanitaria
ID : PS09/02457
Organisme : Fondo de Investigación Sanitaria
ID : PS09/00716
Organisme : Fondo de Investigación Sanitaria
ID : PS
Organisme : Fondo de Investigación Sanitaria
ID : 09/01511
Organisme : Fondo de Investigación Sanitaria
ID : PS09/02185
Organisme : Fondo de Investigación Sanitaria
ID : PS09/03190
Organisme : Servicio Andaluz de Salud, Sociedad Española de Neumología y Cirurgía Torácica
ID : 1001/2010
Organisme : Barcelona-Fondo de Investigación Sanitaria
ID : PS09/00716
Organisme : Galdakao-Fondo de Investigación Sanitaria
ID : 09/01511
Organisme : "Centro de Excelencia Severo Ochoa 2019-2023" Program
ID : CEX2018-000806-S
Organisme : Generalitat de Catalunya through the CERCA Program
Organisme : Swedish Heart and Lung Foundation
Organisme : Swedish Asthma and Allergy Association
Organisme : Swedish Association against Lung and Heart Disease
Organisme : Swedish Research Council for Health, Working Life and Welfare (FORTE)
Organisme : Swedish Council for Working Life and Social Research
Organisme : Västerbotten County Council ALF
Organisme : UBS Wealth Foundation
Organisme : Talecris Biotherapeutics GmbH, Abbott Diagnostics, European Commission
ID : 018996
Organisme : National Institute for Health Research through the Primary Care Research Network
Organisme : Medical Research Council
ID : 92091
Pays : United Kingdom
Organisme : CSP VA
ID : 562
Pays : United States
Organisme : Swiss National Science Foundation
ID : 33CSCO
Pays : Switzerland
Organisme : Swiss National Science Foundation
ID : -134276/1
Pays : Switzerland
Organisme : Swiss National Science Foundation
ID : 33CSCO-108796
Pays : Switzerland
Organisme : Swiss National Science Foundation
ID : 3247BO-104283
Pays : Switzerland
Organisme : Swiss National Science Foundation
ID : 3247BO-104288
Pays : Switzerland
Organisme : Swiss National Science Foundation
ID : 3247BO-104284
Pays : Switzerland
Organisme : Swiss National Science Foundation
ID : 3247-065896
Pays : Switzerland
Organisme : Swiss National Science Foundation
ID : 3100-059302
Pays : Switzerland
Organisme : Swiss National Science Foundation
ID : 3200-052720
Pays : Switzerland
Organisme : Swiss National Science Foundation
ID : 3200-042532
Pays : Switzerland
Organisme : Swiss National Science Foundation
ID : 4026-028099
Pays : Switzerland
Organisme : Wellcome Trust
ID : 084703MA
Pays : United Kingdom
Informations de copyright
© 2021 The Authors. Clinical & Experimental Allergy published by John Wiley & Sons Ltd.
Références
Janson C, Anto J, Burney P, et al. The European Community Respiratory Health Survey: what are the main results so far? European Community Respiratory Health Survey II. Eur Respir J. 2001;18(3):598-611.
To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204.
Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8-160.
Corren J. The connection between allergic rhinitis and bronchial asthma. Curr Opin Pulm Med. 2007;13(1):13-18.
Ciprandi G, Cirillo I, Tosca MA, Vizzaccaro A. Bronchial hyperreactivity and spirometric impairment in patients with perennial allergic rhinitis. Int Arch Allergy Immunol. 2004;133(1):14-18.
Haccuria A, Van Muylem A, Malinovschi A, Doan V, Michils A. Small airways dysfunction: the link between allergic rhinitis and allergic asthma. Eur Respir J. 2018;51(2):1701749.
Polosa R, Ciamarra I, Mangano G, et al. Bronchial hyperresponsiveness and airway inflammation markers in nonasthmatics with allergic rhinitis. Eur Respir J. 2000;15(1):30-35.
Tatar M, Petriskova J, Zucha J, et al. Induced sputum eosinophils, bronchial reactivity, and cough sensitivity in subjects with allergic rhinitis. J Physiol Pharmacol. 2005;56(Suppl 4):227-236.
Giavina-Bianchi P, Aun MV, Takejima P, Kalil J, Agondi RC. United airway disease: current perspectives. J Asthma Allergy. 2016;9:93-100.
Aguilar D, Pinart M, Koppelman GH, et al. Computational analysis of multimorbidity between asthma, eczema and rhinitis. PLoS One. 2017;12(6):e0179125.
Garcia-Aymerich J, Benet M, Saeys Y, et al. Phenotyping asthma, rhinitis and eczema in MeDALL population-based birth cohorts: an allergic comorbidity cluster. Allergy. 2015;70(8):973-984.
Boonpiyathad T, Sozener ZC, Satitsuksanoa P, Akdis CA. Immunologic mechanisms in asthma. Semin Immunol. 2019;46:101333.
Matucci A, Vultaggio A, Maggi E, Kasujee I. Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question? Respir Res. 2018;19(1):113.
Forstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33(7):829-837, 837a-837d.
Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J. 1993;6(9):1368-1370.
Scott M, Raza A, Karmaus W, et al. Influence of atopy and asthma on exhaled nitric oxide in an unselected birth cohort study. Thorax. 2010;65(3):258-262.
Roos AB, Mori M, Gronneberg R, et al. Elevated exhaled nitric oxide in allergen-provoked asthma is associated with airway epithelial iNOS. PLoS One. 2014;9(2):e90018.
Kharitonov SA, Yates DH, Barnes PJ. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med. 1996;153(1):454-457.
Taylor DR. Advances in the clinical applications of exhaled nitric oxide measurements. J Breath Res. 2012;6(4):47102.
Dressel H, de la Motte D, Reichert J, et al. Exhaled nitric oxide: independent effects of atopy, smoking, respiratory tract infection, gender and height. Respir Med. 2008;102(7):962-969.
Frank TL, Adisesh A, Pickering AC, et al. Relationship between exhaled nitric oxide and childhood asthma. Am J Respir Crit Care Med. 1998;158(4):1032-1036.
Patelis A, Gunnbjornsdottir M, Malinovschi A, et al. Population-based study of multiplexed IgE sensitization in relation to asthma, exhaled nitric oxide, and bronchial responsiveness. J Allergy Clin Immunol. 2012;130(2):397-402.e2.
Jouaville LF, Annesi-Maesano I, Nguyen LT, Bocage AS, Bedu M, Caillaud D. Interrelationships among asthma, atopy, rhinitis and exhaled nitric oxide in a population-based sample of children. Clin Exp Allergy. 2003;33(11):1506-1511.
Lee KJ, Cho SH, Lee SH, et al. Nasal and exhaled nitric oxide in allergic rhinitis. Clin Exp Otorhinolaryngol. 2012;5(4):228-233.
Rachel M, Biesiadecki M, Aebisher D, Galiniak S. Exhaled nitric oxide in pediatric patients with respiratory disease. J Breath Res. 2019;13(4):46007.
Ricciardolo FL, Sorbello V, Bellezza Fontana R, Schiavetti I, Ciprandi G. Exhaled nitric oxide in relation to asthma control: a real-life survey. Allergol Immunopathol (Madr). 2016;44(3):197-205.
Khan A, Huynh TMT, Vandeplas G, et al. The GALEN rhinosinusitis cohort: chronic rhinosinusitis with nasal polyps affects health-related quality of life. Rhinology. 2019;57(5):343-351.
Canonica GW, Malvezzi L, Blasi F, et al. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: evidences from the Severe Asthma Network Italy (SANI) registry. Respir Med. 2020;166:105947.
Maniscalco M, Calabrese C, D'Amato M, et al. Association between exhaled nitric oxide and nasal polyposis in severe asthma. Respir Med. 2019;152:20-24.
Kobayashi Y, Asako M, Ooka H, Kanda A, Tomoda K, Yasuba H. Residual exhaled nitric oxide elevation in asthmatics is associated with eosinophilic chronic rhinosinusitis. J Asthma. 2015;52(10):1060-1064.
Galli J, Montuschi P, Passali GC, Laruffa M, Parrilla C, Paludetti G. Exhaled nitric oxide measurement in patients affected by nasal polyposis. Otolaryngol Head Neck Surg. 2012;147(2):351-356.
Guida G, Rolla G, Badiu I, et al. Determinants of exhaled nitric oxide in chronic rhinosinusitis. Chest. 2010;137(3):658-664.
Burney PG, Luczynska C, Chinn S, Jarvis D. The European community respiratory health survey. Eur Respir J. 1994;7(5):954-960.
Janson C, Accordini S, Cazzoletti L, et al. Pharmacological treatment of asthma in a cohort of adults during a 20-year period: results from the European Community Respiratory Health Survey I, II and III. ERJ Open Res. 2019;5(1):00073-2018.
American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171(8):912-930.
Bousquet PJ, Leynaert B, Neukirch F, et al. Geographical distribution of atopic rhinitis in the European Community Respiratory Health Survey I. Allergy. 2008;63(10):1301-1309.
Newson RB, van Ree R, Forsberg B, et al. Geographical variation in the prevalence of sensitization to common aeroallergens in adults: the GA(2) LEN survey. Allergy. 2014;69(5):643-651.
Kumar R, Gupta N. Exhaled nitric oxide atopy, and spirometry in asthma and rhinitis patients in India. Adv Respir Med. 2017;85(4):186-192.
Roberts G, Mylonopoulou M, Hurley C, Lack G. Impairment in quality of life is directly related to the level of allergen exposure and allergic airway inflammation. Clin Exp Allergy. 2005;35(10):1295-1300.
Janson C, Kalm-Stephens P, Foucard T, Norback D, Alving K, Nordvall SL. Exhaled nitric oxide levels in school children in relation to IgE sensitisation and window pane condensation. Respir Med. 2005;99(8):1015-1021.
Franklin PJ, Taplin R, Stick SM. A community study of exhaled nitric oxide in healthy children. Am J Respir Crit Care Med. 1999;159(1):69-73.
Chng SY, Van Bever HP, Lian D, et al. Relationship between exhaled nitric oxide and atopy in Asian young adults. Respirology. 2005;10(1):40-45.
Gupta N, Goel N, Kumar R. Correlation of exhaled nitric oxide, nasal nitric oxide and atopic status: a cross-sectional study in bronchial asthma and allergic rhinitis. Lung India. 2014;31(4):342-347.
Hedman AM, Kuja-Halkola R, Ortqvist AK, van Hage M, Almqvist C, Nordlund B. Genetic effects of allergen-specific IgE levels on exhaled nitric oxide in schoolchildren with asthma: the STOPPA twin study. Pediatr Allergy Immunol. 2021;32(4):709-717.
Olin AC, Alving K, Toren K. Exhaled nitric oxide: relation to sensitization and respiratory symptoms. Clin Exp Allergy. 2004;34(2):221-226.
Neelamegan R, Saka V, Tamilarasu K, Rajaram M, Selvarajan S, Chandrasekaran A. Clinical utility of fractional exhaled nitric oxide (FeNO) as a biomarker to predict severity of disease and response to inhaled corticosteroid (ICS) in asthma patients. J Clin Diagn Res. 2016;10(12):FC01-FC06.
Ciprandi G, Gallo F, Ricciardolo FL, Cirillo I. Fractional exhaled nitric oxide: a potential biomarker in allergic rhinitis? Int Arch Allergy Immunol. 2017;172(2):99-105.
Di Cara G, Marcucci F, Palomba A, et al. Exhaled nitric oxide in children with allergic rhinitis: a potential biomarker of asthma development. Pediatr Allergy Immunol. 2015;26(1):85-87.
Muntean IA, Bocsan IC, Vesa S, et al. Could FeNO predict asthma in patients with house dust mites allergic rhinitis? Medicina (Kaunas). 2020;56(5):235.
Malinovschi A, Alving K, Kalm-Stephens P, Janson C, Nordvall L. Increased exhaled nitric oxide predicts new-onset rhinitis and persistent rhinitis in adolescents without allergic symptoms. Clin Exp Allergy. 2012;42(3):433-440.
Oka A, Matsunaga K, Kamei T, et al. Ongoing allergic rhinitis impairs asthma control by enhancing the lower airway inflammation. J Allergy Clin Immunol Pract. 2014;2(2):172-178.
Pedroletti C, Lundahl J, Alving K, Hedlin G. Effect of nasal steroid treatment on airway inflammation determined by exhaled nitric oxide in allergic schoolchildren with perennial rhinitis and asthma. Pediatr Allergy Immunol. 2008;19(3):219-226.
Kersten ET, van Leeuwen JC, Brand PL, et al. Effect of an intranasal corticosteroid on exercise induced bronchoconstriction in asthmatic children. Pediatr Pulmonol. 2012;47(1):27-35.
Sapsaprang S, Tanticharoenwiwat P, Kulalert P, Poachanukoon O, Setabutr D. Comparison of exhaled nitric oxide levels in pediatric patients with allergic rhinitis. Int J Pediatr Otorhinolaryngol. 2019;126:109603.
Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-1650.
Bousquet PJ, Chinn S, Janson C, et al. Geographical variation in the prevalence of positive skin tests to environmental aeroallergens in the European Community Respiratory Health Survey I. Allergy. 2007;62(3):301-309.